These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23888878)

  • 1. Genome engineering with TAL-effector nucleases and alternative modular nuclease technologies.
    Scharenberg AM; Duchateau P; Smith J
    Curr Gene Ther; 2013 Aug; 13(4):291-303. PubMed ID: 23888878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CRISPR/Cas9 system for plant genome editing and beyond.
    Bortesi L; Fischer R
    Biotechnol Adv; 2015; 33(1):41-52. PubMed ID: 25536441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designed nucleases for targeted genome editing.
    Lee J; Chung JH; Kim HM; Kim DW; Kim H
    Plant Biotechnol J; 2016 Feb; 14(2):448-62. PubMed ID: 26369767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome engineering via TALENs and CRISPR/Cas9 systems: challenges and perspectives.
    Mahfouz MM; Piatek A; Stewart CN
    Plant Biotechnol J; 2014 Oct; 12(8):1006-14. PubMed ID: 25250853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of Engineered DNA-Binding Molecules Such as TAL Proteins and the CRISPR/Cas System in Biology Research.
    Fujita T; Fujii H
    Int J Mol Sci; 2015 Sep; 16(10):23143-64. PubMed ID: 26404236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining the specificities of TALENs, Cas9, and other genome-editing enzymes.
    Pattanayak V; Guilinger JP; Liu DR
    Methods Enzymol; 2014; 546():47-78. PubMed ID: 25398335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of Alternative Nucleases in the Age of CRISPR/Cas9.
    Guha TK; Edgell DR
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A guide to genome engineering with programmable nucleases.
    Kim H; Kim JS
    Nat Rev Genet; 2014 May; 15(5):321-34. PubMed ID: 24690881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Origins of Programmable Nucleases for Genome Engineering.
    Chandrasegaran S; Carroll D
    J Mol Biol; 2016 Feb; 428(5 Pt B):963-89. PubMed ID: 26506267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monomeric site-specific nucleases for genome editing.
    Kleinstiver BP; Wolfs JM; Kolaczyk T; Roberts AK; Hu SX; Edgell DR
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8061-6. PubMed ID: 22566637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research progress of genome editing and derivative technologies in plants.
    Shan QW; Gao CX
    Yi Chuan; 2015 Oct; 37(10):953-73. PubMed ID: 26496748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A guide for drug inducible genome editing with HIT systems.
    Zhao C; Wei S; Wang Y
    Methods Enzymol; 2019; 621():53-68. PubMed ID: 31128789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CRISPR-Cas system for plant genome editing: advances and opportunities.
    Kumar V; Jain M
    J Exp Bot; 2015 Jan; 66(1):47-57. PubMed ID: 25371501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing.
    Hendel A; Kildebeck EJ; Fine EJ; Clark J; Punjya N; Sebastiano V; Bao G; Porteus MH
    Cell Rep; 2014 Apr; 7(1):293-305. PubMed ID: 24685129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9; A robust technology for producing genetically engineered plants.
    Farooq R; Hussain K; Nazir S; Javed MR; Masood N
    Cell Mol Biol (Noisy-le-grand); 2018 Nov; 64(14):31-38. PubMed ID: 30511631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CRISPR/Cas system for genome editing in pluripotent stem cells].
    Vasil'eva EA; Melino D; Barlev NA
    Tsitologiia; 2015; 57(1):19-30. PubMed ID: 25872372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Practical Guide to Genome Editing Using Targeted Nuclease Technologies.
    Porter SN; Levine RM; Pruett-Miller SM
    Compr Physiol; 2019 Mar; 9(2):665-714. PubMed ID: 30873595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of CRISPR/Cas9 system for targeted DNA modifications and recent improvements in modification efficiency and specificity.
    Shin J; Oh JW
    BMB Rep; 2020 Jul; 53(7):341-348. PubMed ID: 32580834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.